RxDoctor Payments Data

Arkady Gendelman, MD

Family Medicine · San Francisco, CANPI 1104839620

Payments from drug & device makers

$15,097in general payments, 2019–2025

Across 498 payments — averaging $30.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • Amgen$1K
  • Novo Nordisk$785
  • plus $7K from 37 others

What the payments were for

  • Food & beverage$15,072100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,097 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$240,739
Medicare patients
171
Services billed
2,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$67,817
MounjaroTirzepatide45$54,813
EliquisApixaban64$47,563
LinzessLinaclotide59$36,286
FarxigaDapagliflozin Propanediol22$24,160
OzempicSemaglutide15$14,061
DayvigoLemborexant38$12,792
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$12,735
Spiriva RespimatTiotropium Bromide16$10,424
Repatha SureclickEvolocumab15$8,284
VascepaIcosapent Ethyl22$7,161
Memantine Hcl69$6,181
ArexvyRsvpref3 Antigen/As01e/Pf16$4,944
MyrbetriqMirabegron11$4,798
Aripiprazole13$4,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$1,118$90,976111 claims
Lilly USA, LLCMounjaro$1,964$54,81345 claims
PfizerEliquis$585$47,56364 claims
AbbVieLinzess, Synthroid$2,193$38,07872 claims
AstraZenecaFarxiga$1,138$24,16022 claims
Novo NordiskOzempic$785$14,06115 claims
Eisai Inc.Dayvigo$271$12,79238 claims
GSKArexvy$441$4,94416 claims
Astellas Pharma US IncMyrbetriq$90$4,79811 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$19$3,09114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →